Related Experiment Video
Updated: Jun 12, 2026
Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
Published on: November 18, 2019
Proteomics and ovarian cancer: integrating proteomics information into clinical care
John L Hays1, Geoffrey Kim, Iulia Giuroiu
1Molecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1906, USA. haysjl@mail.nih.gov
Abstract:
The power of proteomics allows unparalleled opportunity to query the molecular mechanisms of a malignant cell and the tumor microenvironment in patients with ovarian cancer and other solid tumors. This information has given us insight into the perturbations of signaling pathways within tumor cells and has aided the discovery of new drug targets for the tumor and possible prognostic indicators of outcome and disease response to therapy. Proteomics analysis of serum and ascites has also given us sources with which to discover possible early markers for the presence of new disease and for the progression of established cancer throughout the course of treatment. Unfortunately, this wealth of information has yielded little to date in changing the clinical care of these patients from a diagnostic, prognostic, or treatment perspective. The rational examination and translation of proteomics data in the context of past clinical trials and the design of future clinical trials must occur before we can march forward into the future of personalized medicine.
Insights
Proteomics offers deep insights into ovarian cancer molecular mechanisms and potential drug targets. However, translating this data into improved patient care requires further clinical trial examination and design.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- Proteomics provides insights into molecular mechanisms of ovarian cancer and solid tumors.
- It aids in discovering drug targets and prognostic indicators for patient outcomes and therapy response.
- Proteomics analysis of serum and ascites can reveal early disease markers and track cancer progression.
Purpose of the Study:
- To explore the potential of proteomics in understanding ovarian cancer and other solid tumors.
- To identify how proteomics data can inform drug discovery and prognostic indicators.
- To assess the current impact of proteomics on clinical care and future directions.
Main Methods:
- Proteomics analysis of tumor cells, tumor microenvironment, serum, and ascites.
- Investigation of signaling pathway perturbations.
- Review of existing clinical trial data and future trial design considerations.
Main Results:
- Proteomics has provided significant insight into tumor cell signaling and identified potential drug targets.
- Serum and ascites proteomics have shown promise for early detection and monitoring of cancer progression.
- Despite the wealth of data, proteomics has had limited impact on current clinical patient care.
Conclusions:
- Proteomics holds great promise for advancing personalized medicine in oncology.
- Rational examination and translation of proteomics data are crucial for clinical application.
- Future clinical trial design must incorporate proteomics findings to improve patient diagnosis, prognosis, and treatment.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
09:52A Clinical Metaproteomics Workflow Implemented within Galaxy Bioinformatics Platform to Analyze Host-Microbiome Interactions Underlying Human Disease
Published on: January 10, 2025
